Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) closed its last session at $2.48 with the change of +26.53%. The market capitalization of the company is $38.17M with an average Volume of 3.89 million shares. The stock currently has its 52-Week High range of $8.00 and 52-week low range of $0.25. The Price to Book (P/B) ratio stands at 3.23. The stock traded total quantity of 17.32 million shares.
The Company currently has Highest Price Target of $12 and Lowest Price Target of $12. It has Median Price Targets of $12. Mean price target is set at $12 after consensus analysis of 1 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 12 analysts have assigned this stock as Strong Buy where 12 assigned Buy, 12 analysts believe it’s a Hold, 12 said Underperform and 1 assigned Sell rating.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended its last trade at $0.445 with the move of +3.440%. The company has market value of $64.78M with the total traded volume of 1.62 million. The stock currently has its 52-Week top value of $4.920 and 52-week down value of $0.350. The price to book (P/B) ratio of the company is 5.736. Its previous closing price was recorded at $0.430.
For the current Fiscal Quarter, 7 analysts have given an Average earnings estimate of $-0.13 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.16 while High Estimate is $-0.07. The Previous Year EPS of this Quarter is $-0.18.
According to 7 analysts, an Average Revenue Estimate of the current Fiscal quarter is $7.34M. According to them, the Low Revenue estimate is $4.86M and High Revenue estimate is $10.00M.
The Company currently has High Price Target of $2. The Low and Mean Price Targets are $0.5 and $1.22 respectively. These price targets are set after consensus analysis of 5 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 0 analysts have given this stock as Strong Buy where 0 issued Buy, 6 analysts think that it’s a Hold, 1 told Underperform and0 assigned Sell rating.